Chinook Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Chinook Therapeutics is Eric Dobmeier, benoemd in Apr2019, heeft een ambtstermijn van 4.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.84M, bestaande uit 12.4% salaris en 87.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.42% van de aandelen van het bedrijf, ter waarde $ 12.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 3.5 jaar.

Belangrijke informatie

Eric Dobmeier

Algemeen directeur

US$4.8m

Totale compensatie

Percentage CEO-salaris	12.4%
Dienstverband CEO	4.3yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	3.5yrs

Recente managementupdates

Recent updates

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

May 28

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

Feb 14

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Aug 31

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Aug 12

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Aug 08

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Jul 05

Analyse CEO-vergoeding

Hoe is Eric Dobmeier's beloning veranderd ten opzichte van Chinook Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-US$246m
Mar 31 2023	n/a	n/a	-US$216m
Dec 31 2022	US$5m	US$601k	-US$188m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$92m
Mar 31 2022	n/a	n/a	-US$97m
Dec 31 2021	US$4m	US$547k	-US$103m
Sep 30 2021	n/a	n/a	-US$160m
Jun 30 2021	n/a	n/a	-US$149m
Mar 31 2021	n/a	n/a	-US$114m
Dec 31 2020	US$6m	US$438k	-US$82m

Compensatie versus markt: De totale vergoeding ($USD 4.84M ) Eric } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.50M ).

Compensatie versus inkomsten: De vergoeding van Eric is gestegen terwijl het bedrijf verliesgevend is.

CEO

Eric Dobmeier (54 yo)

4.3yrs

Tenure

US$4,841,699

Compensatie

Mr. Eric L. Dobmeier, J.D., has been an Independent Director at Structure Therapeutics Inc. since December 2022. He is the President, Chief Executive Officer and Director of Chinook Therapeutics, Inc. sinc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Eric Dobmeier	President	4.3yrs	US$4.84m	0.42% $ 12.2m
Tom Frohlich	Chief Operating Officer	2.2yrs	US$2.02m	0.21% $ 6.1m
Andrew King	Chief Scientific Officer	2.2yrs	US$2.23m	0.027% $ 773.8k
Eric Bjerkholt	Chief Financial Officer	2.8yrs	geen gegevens	0.054% $ 1.6m
Sukhi Thethy	Senior Vice President of Finance & Accounting	less than a year	geen gegevens	geen gegevens
Noopur Liffick	Senior Vice President of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Kirk Schumacher	Senior VP & General Counsel	no data	geen gegevens	geen gegevens
Jodi Jamieson	Senior Vice President of Human Resources	no data	geen gegevens	geen gegevens
Alan Glicklich	Executive Officer	3.3yrs	US$2.41m	0.011% $ 318.7k
Delphine Imbert	Senior Vice President of CMC & Technical Operations	2.3yrs	geen gegevens	geen gegevens
Charlotte Jones-Burton	Senior Vice President of Product Development & Strategy	1.6yrs	geen gegevens	geen gegevens
Andrew Oxtoby	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KDNY wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Eric Dobmeier	President	4.3yrs	US$4.84m	0.42% $ 12.2m
Michelle Griffin	Independent Director	2.8yrs	US$233.60k	0.0046% $ 133.4k
Srinivas Akkaraju	Independent Director	4.1yrs	US$227.60k	0.0046% $ 133.4k
William Greenman	Independent Director	13.2yrs	US$233.10k	0.033% $ 955.0k
Mahesh Krishnan	Independent Director	1.4yrs	US$451.98k	0.0018% $ 51.6k
Jerel Davis	Independent Lead Director	4.7yrs	US$244.60k	0.62% $ 18.1m
Robert Azelby	Independent Director	less than a year	geen gegevens	0% $ 0
Dolca Thomas	Independent Director	2.8yrs	US$217.60k	0.019% $ 537.1k

3.5yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KDNY wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Chinook Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

President recently sold US$190k worth of stock

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Price target increased by 7.8% to US$39.45

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

New major risk - Share price stability

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

President recently sold US$190k worth of stock

Chief Scientific Officer exercised options and sold US$191k worth of stock

Chief Operating Officer exercised options and sold US$246k worth of stock

President exercised options and sold US$657k worth of stock

Consensus forecasts updated

Chief Operating Officer notifies of intention to sell stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Operating Officer exercised options and sold US$217k worth of stock

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Chief Operating Officer exercised options and sold US$145k worth of stock

Independent Director recently bought US$212k worth of stock

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Consensus revenue estimates fall by 14%

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chief Scientific Officer exercised options and sold US$98k worth of stock

Chief Scientific Officer exercised options and sold US$89k worth of stock

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

High number of new directors

President recently bought US$65k worth of stock

Consensus forecasts updated

Price target increased to US$34.86

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chief Scientific Officer exercised options and sold US$75k worth of stock

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd